+ Translate

The prevention of breast cancer

, : The prevention of breast cancer. British Journal of Surgery 90(7): 772-783

Despite advances in the early detection and treatment of breast carcinoma, the mortality and morbidity rates associated with this disease remain high. Primary prevention, therefore, offers the best chance of making a major impact on outcome. The aim was to review the rationale, current stage of development and adverse effects of the strategies involved in the primary prevention of breast carcinoma. A review of the literature was undertaken by searching the MEDLINE database for the period 1966-2002 without language restrictions. Currently, the only agent to have general approval for chemoprevention of breast carcinoma is tamoxifen. Women who derive the greatest benefit in terms of risk reduction from tamoxifen are premenopausal with a 5-year Gail risk factor of more than 1.66 per cent, postmenopausal with a 5-year Gail risk factor of more than 3 per cent, and postmenopausal without a uterus. In these specific subgroups, tamoxifen should be considered for the chemoprevention of breast carcinoma. Raloxifene, retinoids, aromatase inhibitors and cyclo-oxygenase 2 inhibitors require further clinical investigation before adoption in this context. Surgical intervention should largely be limited to those women who have a BRCA1 or BRCA2 mutation.

(PDF same-day service: $19.90)

Accession: 050698967

PMID: 12854100

DOI: 10.1002/bjs.4218

Submit PDF Full Text: Here

Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:

Related references

Dunn, B.K.; Ford, L.G., 2000: Breast cancer prevention Results of the National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial. European Journal of Cancer 36(Supplement 4): S49-S50, September

Reis, S.E.; Costantino, J.P.; Wickerham, D.L.; Tan-Chiu, E.; Wang, J.; Kavanah, M., 2001: Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. The overall effect of prophylactic tamoxifen in women depends on the balance between the effects of the drug, which include preventing breast cancer and altering cardiovascular risk. In a recent clinical trial, postmenopausal estrogen-progestin th...

Dunn, B.K.; Ford, L.G., 2000: Breast cancer prevention: results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) breast cancer prevention trial (NSABP P-1: BCPT). European Journal of Cancer 36 Suppl 4: S49-S50

Lillquist, P.P., 2001: Breast cancer policy as a paradigm for other health prevention issues: analysis of the Breast and Cervical Cancer Mortality Prevention Act of 1990. The public policy response to breast cancer mortality is examined through an analysis of federal legislation. Departing from the federal government's traditional role in health policy, the legislation funds states to provide directly some hea...

Cuzick, J.; Sestak, I.; Cawthorn, S.; Hamed, H.; Holli, K.; Howell, A.; Forbes, J.F.; Abdi, E.; Anderson, E.; Atkinson, C.; Baum, M.; Beith, J.; Bird, A.; Birrell, S.; Blamey, R.; Blum, R.; Boyages, J.; Buser, K.; Campbell, I.; Cawthorn, S.; Chapman, C.; Chipman, M.; Coates, A.; Collins, J.P.; Craft, P.; Cuzick, J.; Denton, L.; Dewar, J.; Dowsett, M.; Earl, H.; Eccles, D.; Edwards, R.; Evans, G.; Fallowfield, L.; Fentiman, I.; Forbes, J.F.; Friedlander, M.; Garcia, J.; George, W.; Gilbert, F.J.;, 2015: Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Four previously published randomised clinical trials have shown that tamoxifen can reduce the risk of breast cancer in healthy women at increased risk of breast cancer in the first 10 years of follow-up. We report the long-term follow-up of the IB...

Wang, J.; Costantino, J.P.; Tan Chiu, E.; Wickerham, D.L.; Wolmark, N., 2002: Benign breast disease and the risk of subsequent invasive breast cancer Findings from the National Surgical Adjuvant Breast and Bowel Projects breast cancer prevention trial. Breast Cancer Research & Treatment 76(Supplement 1): S36, December

Wolmark, N.; Dunn, B.K., 2002: The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). The Breast Cancer Prevention Trial (P-1: BCPT) of the National Surgical Adjuvant Breast and Bowel Project (NSABP) randomized 13,388 women, > or = 35 years of age, at increased risk for breast cancer [> or = 1.66% by Gail model criteria or wi...

Feigelson, H.S.; Henderson, B.E., 2001: Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention. Risk factors for breast cancer are related to endogenous hormones and reproductive events. As such, traditional cancer prevention strategies are not easily applicable. Tamoxifen and other selective estrogen receptor modulators (SERMs) offer a new...

Crowell, E.B.; Jubelirer, S.J., 2001: Breast cancer risks and prevention: implications of the Breast Cancer Prevention Trial results. Breast cancer is a major health concern for women in the U.S. Several factors determine a woman's risk for developing breast cancer including age, genetics, hormonal exposure and others. It is possible to estimate a woman's risk for deve...

Vogel, V.G., 2002: Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Women who are at increased risk for developing breast cancer can be identified using quantitative risk assessment models that provide valid estimates of risk. The Breast Cancer Prevention Trial (BCPT, P-1) demonstrated that tamoxifen can reduce th...